Your browser doesn't support javascript.
loading
A687V EZH2 is a driver of histone H3 lysine 27 (H3K27) hypertrimethylation.
Ott, Heidi M; Graves, Alan P; Pappalardi, Melissa B; Huddleston, Michael; Halsey, Wendy S; Hughes, Ashley M; Groy, Arthur; Dul, Edward; Jiang, Yong; Bai, Yuchen; Annan, Roland; Verma, Sharad K; Knight, Steven D; Kruger, Ryan G; Dhanak, Dashyant; Schwartz, Benjamin; Tummino, Peter J; Creasy, Caretha L; McCabe, Michael T.
Afiliação
  • Ott HM; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Graves AP; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Pappalardi MB; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Huddleston M; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Halsey WS; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Hughes AM; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Groy A; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Dul E; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Jiang Y; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Bai Y; Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Annan R; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Verma SK; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Knight SD; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Kruger RG; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Dhanak D; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Schwartz B; Platform Technology and Science, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Tummino PJ; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • Creasy CL; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. Molecular Medicine Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania.
  • McCabe MT; Cancer Epigenetics Discovery Performance Unit, Cancer Research, Oncology R&D, GlaxoSmithKline, Collegeville, Pennsylvania. michael.t.mccabe@gsk.com.
Mol Cancer Ther ; 13(12): 3062-73, 2014 Dec.
Article em En | MEDLINE | ID: mdl-25253781
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Histonas / Complexo Repressor Polycomb 2 / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Histonas / Complexo Repressor Polycomb 2 / Mutação Tipo de estudo: Prognostic_studies Limite: Humans Idioma: En Ano de publicação: 2014 Tipo de documento: Article